When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?
Publication: Annals of Internal Medicine
Volume 147, Number 1
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al; Asian-Pacific Consensus Update Working Party on Chronic Hepatitis B. Asian-Pacific Consensus Statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472-89. [PMID: 15910483]
2.
de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al; EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1 S3-25. [PMID: 14708673]
3.
Lok AS, McMahon BJ; Practice Guidelines Committee. American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857-61. [PMID: 14999707]
4.
Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007;147:58-61.
5.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-39. [PMID: 17256718]
6.
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10. [PMID: 12093239]
7.
Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983. [PMID: 15028636]
8.
Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610-4. [PMID: 15871997]
9.
Nguyen M, Trinh H, Garcia T, Ahmed A, Keeffe E. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation [Abstract]. Hepatology. 2005;42:593A. Abstract no. 1008.
10.
Lai M, Hyatt B, Afdahl N. Role of liver biopsy in patients with normal ALT and high HBV DNA [Abstract]. Hepatology. 2005;42:720A. Abstract no. 1322.
11.
Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-81. [PMID: 16447285]
12.
Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829-34.
13.
Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408-15. [PMID: 12447866]
14.
Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588-91. [PMID: 2570285]
15.
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-7. [PMID: 12029639]
16.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673-81. [PMID: 15987916]
17.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-51. [PMID: 17087951]
18.
Chang T, Chao YC, Kaymakoglu S, Cheinquer H, Pesoa M, Gish R, et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral naive HBeAg(+) patients (ETV 022/901) [Abstract]. Hepatology. 2006;44:229A. Abstract no. 109.
19.
Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186-94. [PMID: 12085364]
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 147 • Number 1 • 3 July 2007
Pages: 62 - 64
History
Published online: 3 July 2007
Published in issue: 3 July 2007
Keywords
- Aminotransferases
- Biochemistry
- DNA
- Drug therapy
- Enzymes
- Enzymology
- Genetics
- Health care
- Health care policy
- Health services administration and management
- Hepatitis B
- Hospital medicine
- Infectious diseases
- Infectious hepatitis
- Liver diseases
- Nucleosides
- Patients
- Prevention, policy, and public health
- Research and reporting methods
- Transferases
Copyright
© 2007 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?. Ann Intern Med.2007;147:62-64. [Epub 3 July 2007]. doi:10.7326/0003-4819-147-1-200707030-00011
When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?. Ann Intern Med.2007;147:62-64. [Epub 3 July 2007]. doi:10.7326/0003-4819-147-1-200707030-00011
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.